A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer

Inclusion Criteria

• Participants with suspected or histologically confirmed Stage IIA (> 4 cm) to IIIB (T3N2) non-small cell lung carcinoma (NSCLC) with disease that is considered resectable
• No brain metastasis
• Treatment-naive for NSCLC (no prior systemic anti-cancer treatment)
• Ability to provide surgical or biopsy tumor tissue for biomarkers
• Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1

Exclusion Criteria

• Participants with an active, known or suspected autoimmune disease
• Any positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV)
• Any previous anti-cancer treatment including cytotoxic, IO treatment, targeted agents, or radiotherapy for NSCLC
• Prior treatment with any anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways Other protocol-defined inclusion/exclusion criteria apply